Microneedles for treatment of peanut allergy

微针治疗花生过敏

• 批准号: 10471226
• 负责人: Harvinder Singh Gill
• 金额: $ 63.27万
• 依托单位: TEXAS TECH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-17 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10471226
• 关键词: Adverse effects; Allergen Immunotherapy; Allergens; Allergic Disease; Allergy Shot; Allergy to peanuts; Anaphylaxis; Anatomy; Animals; Antibodies; Antigens; Area; Attention; Autoimmune Diseases; Behavior; Biomedical Engineering; Body Weight decreased; Bone Marrow; Child; Clinic; Clinical Trials; Cutaneous; Data; Deposition; Development; Diarrhea; Diet; Dose; Effectiveness; Ensure; Erythema; Exhibits; Exposure to; FDA approved; Family; Family suidae; Food; Food Hypersensitivity; Foundations; Generations; Gills; Goals; Hemorrhage; Histologic; Human; Hypersensitivity; IgG4; Immune; Immune response; Immunoglobulin G; Immunoglobulin-Secreting Cells; Immunology; Immunotherapy; Intestines; Langerhans cell; Lead; Length; Life; Life Style; Malnutrition; Medicine; Modeling; Mus; Neonatal; Oral; Passive Immunization; Patients; Pediatric Hospitals; Personal Satisfaction; Persons; Phase; Phenotype; Physiology; Plasma Cells; Play; Population; Production; Regulatory T-Lymphocyte; Research; Respiratory distress; Risk; Role; Safety; Skin; Stress; Technology; Texas; Therapeutic Effect; Treatment Efficacy; acute symptom; base; biological adaptation to stress; comparative; desensitization; design; environmental allergy; immunogenicity; in vivo; milligram; mouse model; novel; oral immunotherapy; porcine model; prevent; programs; side effect; success; therapeutic effectiveness; uptake; vaccinology

Microneedles for treatment of peanut allergy Peanut allergy is a life-threatening condition. About 1% of the US population (~3 million people) has peanut allergies, and there is no FDA-approved treatment. Strict avoidance, and a peanut-free diet is the only option available to manage peanut allergies, which imposes severe limitations on the lifestyle of the patient and their families, and can lead to nutritional deficiencies. The overall goal of this proposal is to develop a coated microneedles (MNs) based cutaneous immunotherapy (CIT) a.k.a (MNs-CIT) for peanut allergy. Presently peanut oral immunotherapy has received much attention. However, a major limitation of oral immunotherapy is that the peanut oral dose is escalated to thousands of milligrams, which causes adverse effects. Based on our preliminary data our hypothesis is that MNs coated with peanut allergen can safely deliver peanut allergen in to the superficial skin-layer to produce long-lasting peanut desensitization. Our specific aims are: (i) Develop PE- coated MNs and evaluate their short and long term therapeutic effectiveness in treating peanut allergy, (ii) Characterize the mechanism of peanut MNs-CIT, and (iii) Evaluate therapeutic efficacy in a neonatal pig model of peanut allergy. If successful, these studies will provide the foundation to support the development of a novel and safer peanut allergy immunotherapy treatment.

微针治疗花生过敏 花生过敏是一种威胁生命的疾病。大约1％的美国人口（约300万人）有花生 过敏，也没有FDA批准的治疗方法。严格回避，无花生饮食是唯一的选择 可用于管理花生过敏，这对患者的生活方式施加了严重的限制 家庭，并可能导致营养缺陷。该提案的总体目标是开发一个涂层 微针（MNS）的皮肤免疫疗法（CIT）又称花生过敏。目前 花生口服免疫疗法受到了很多关注。但是，口服免疫疗法的主要局限性是 花生口服剂量升级为数千毫克，这会引起不良影响。基于我们 初步数据我们的假设是用花生过敏原涂层的MN可以安全地递送花生过敏到 浅表皮层可产生持久的花生脱敏。我们的具体目的是：（i）发展 涂层MN并评估其在治疗花生过敏方面的短期和长期治疗有效性，（ii） 表征花生MNS-CIT的机制，（iii）评估新生儿猪模型中的治疗功效 花生过敏。 如果成功，这些研究将为支持新颖和更安全的花生的发展提供基础 过敏免疫治疗。

项目成果

Targeted allergen-specific immunotherapy within the skin improves allergen delivery to induce desensitization to peanut.

皮肤内的靶向过敏原特异性免疫疗法可改善过敏原的传递，从而诱导对花生的脱敏。

• DOI: 10.2217/imt-2021-0206
• 发表时间: 2022
• 期刊: Immunotherapy
• 影响因子: 2.8
• 作者: Landers,JeffreyJ;Janczak,KatarzynaW;Shakya,AkhileshKumar;Zarnitsyn,Vladimir;Patel,SamirkumarR;BakerJr,JamesR;Gill,HarvinderSingh;O'Konek,JessicaJ
• 通讯作者: O'Konek,JessicaJ